Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -345.79M | -334.33M | -339.45M | -297.11M | -246.63M |
| Total Depreciation and Amortization | 758.00K | 795.00K | 787.00K | 717.00K | 643.00K |
| Total Amortization of Deferred Charges | 2.41M | 2.19M | 2.13M | 2.33M | 1.86M |
| Total Other Non-Cash Items | 77.13M | 79.87M | 95.00M | 88.00M | 81.53M |
| Change in Net Operating Assets | -17.19M | -15.30M | -5.59M | -9.38M | -4.33M |
| Cash from Operations | -282.68M | -266.77M | -247.11M | -215.45M | -166.93M |
| Capital Expenditure | -113.00K | -135.00K | -605.00K | -1.50M | -1.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -113.00K | -135.00K | -605.00K | -1.50M | -1.46M |
| Total Debt Issued | 49.50M | 59.40M | 246.64M | 246.64M | 221.89M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 123.37M | 123.37M | 122.08M | 34.00K | 141.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 172.87M | 182.77M | 368.72M | 246.68M | 363.41M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -109.92M | -84.13M | 121.01M | 29.73M | 195.02M |